A phase II study of tasisulam sodium (LY573636) as second-line treatment for patients with unresectable or metastatic melanoma

J. M. Kirkwood, R. Gonzalez, D. S. Reinfgen, P. R. Clingan, R. R. McWilliams, R. L. Ilaria, D. P. de Alwis, A. Zimmermann, M. P. Brown, M. Millward

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

5 Citations (Web of Science)
Original languageEnglish
Number of pages1
JournalJournal of Clinical Oncology
Volume28
Issue number15
DOIs
Publication statusPublished - 20 May 2010
Externally publishedYes

Cite this